Navigation Links
MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
Date:4/7/2008

ines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to the further development of MAP0005 and the potential application of MAP Pharmaceuticals' technologies to additional product candidates. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the development and commercialization of product candidates incorporating MAP Pharmaceuticals' technologies. The reader is cautioned not to unduly rely on the forward- looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10K, filed with the SEC on March 20, 2008, available at http://edgar.sec.gov.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
3. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
4. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
5. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
8. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
9. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
10. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
11. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  IRIDEX Corporation (NASDAQ: ... release its second quarter 2014 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, July ... quarter and other business developments. Interested parties ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... OXIS International, Inc. (OTC Bulletin Board: OXIS ... named former Wal-Mart executive Ken Eaton to its Board ... including three independent Directors. "I am very ... the OXIS International Board of Directors," said Anthony J. ...
... June 27, 2011 Pacira Pharmaceuticals, Inc ., ... company, today announced that it has been included in ... its comprehensive set of U.S. and global equity indexes ... 3000 Index measures the performance of the 3,000 largest ...
Cached Medicine Technology:OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors 2OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors 3Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 2Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 3
(Date:7/25/2014)... Yisrayl Hawkins, Pastor and Overseer of The ... the pot by revealing to the whole world, including even ... Satan, the devil, in his new article. , Yisrayl says ... and carried out by the Catholic Church. He says this ... Inspired Holy Scriptures and replacing it with titles such as ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Recently, the largest ... all its members and found that there had been a ... HSV and/or HPV virus. , Living with a sexually transmitted ... as there are many people from all around the world ... been diagnosed with one of many STDs including HSV, HPV, ...
(Date:7/25/2014)... As the category creator and world leader in healthy ... transform and improve individual lives worldwide through its exclusive and ... a successful Austin, Texas based "Xocai Activ Drink" author, is ... July to promote the up and coming mxicorp.com/company/igc Eric Worre ... has been a leader in the Network Marketing Profession for ...
(Date:7/24/2014)... Lawrence, KS (PRWEB) July 25, 2014 ... implant can be affected by the width of the ... to hold the implant. A variety of methods exist, ... and subsequent augmentation techniques. The ridge-split graft is highlighted ... , The Journal of Oral Implantology offers a ...
(Date:7/24/2014)... A few weeks have passed since ... high jump by Inika McPherson is a feat to ... USATF National Championships hosted the best track and field ... won US Nationals with the 2nd best jump in ... the biggest height over head jump in history. , ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:The Number of People Living With HSV and HPV Greatly Increased- Survey on PositiveSingles.com 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 2Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 3Health News:Setting A New High Jump World Record In Zensah® Compression 2Health News:Setting A New High Jump World Record In Zensah® Compression 3
... ... the United States will be working in the fields. Although the United States was one ... continues to allow children to work long hours in hazardous jobs. , ... Washington, D.C.(Vocus) June 11, 2010 -- Today on ...
... ... distribution operations for the company’s new product line, the CR Series Load & Go™ ... ... of a new manufacturing facility in Miramar, Florida. The new facility will support ...
... ... Advanced Imaging Consultants have finalized their partnership, that will make UltraLinq,s exam reporting ... and operations solution for mobile and outreach imaging businesses. , ... New York, NY (PRWEB) ...
... blood supply, but urge more research , SATURDAY, June 12 (HealthDay ... panel of experts on Friday voted to uphold a decades-old ban ... the controversial issue. , The current policy -- put into effect ... prevents any man who since 1977 has had sex with another ...
... will be ineffective , SATURDAY, June 12 (HealthDay ... to treatment for hepatitis C infection has been identified ... 1,362 hepatitis C patients and pinpointed the variant in ... occurs in a gene called IL28B, which encodes for ...
... Leading Gulf Coast medical centers, universities and public health ... a consortium to improve community disaster readiness and recovery ... environmental health. The consortium, known as SECURE ... funded through a two-year, $4 million grant from the ...
Cached Medicine News:Health News:AFOP's Children in the Fields Campaign Raises Awareness of Child Labor in the U.S. 2Health News:AFOP's Children in the Fields Campaign Raises Awareness of Child Labor in the U.S. 3Health News:UltraLinq Healthcare Solutions and Advanced Imaging Consultants Partner to Provide an Anytime, Anywhere Image Management Solution to the Mobile Market 2Health News:UltraLinq Healthcare Solutions and Advanced Imaging Consultants Partner to Provide an Anytime, Anywhere Image Management Solution to the Mobile Market 3Health News:U.S. Panel Upholds Ban on Gay Men as Blood Donors 2Health News:U.S. Panel Upholds Ban on Gay Men as Blood Donors 3Health News:Research alliance aims to help vulnerable communities cope with disaster 2Health News:Research alliance aims to help vulnerable communities cope with disaster 3Health News:Research alliance aims to help vulnerable communities cope with disaster 4
... is the premium CPAP device in ResMeds new ... line of flow generators are the smallest on ... to include an option of fully integrated heated ... for simplicity and convenience. Premium S8 models also ...
... freedom and flexibility with the integrated ... battery pack, the system will be ... Also includes an integrated heated humidifier. ... water for one nights use, and ...
... is the smallest and lightest continuous positive ... It is designed to help active sleep ... with therapy. The GoodKnight 420S model records ... data. It also detects persistent residual apnea, ...
The clarity and performance of glass with shatterproof safety of plastic....
Medicine Products: